Song-Bing H, Hao Z, Jian Z, Guo-Qiang Z, Tuo H, Dai-Wei W, Wen G, Lin G, Yi Z, Xiao-Feng
X, Li-Feng Z, Min F, Shui-Qing H, Xiao-Dong Y, Xin-Guo Z, Liang W, De-Chun L. Inhibition
of EZH2 expression is associated with the proliferation, apoptosis and migration of SW620
colorectal cancer cells in vitro. Experimental Biology and Medicine July
8, 2014. doi: 10.1177/1535370214542215
A previous Online First version of the article ‘Inhibition of EZH2 expression is
associated with the proliferation, apoptosis and migration of SW620 colorectal cancer
cells in vitro’, first published on July 8, 2014 as doi: 10.1177/1535370214542215, has
been amended in the current version of record as below. Text in red indicates changes made
to the original published version, requested because of unattributed duplication.
Inhibition of EZH2 expression is associated with the proliferation, apoptosis and
migration of SW620 colorectal cancer cells in vitro
Get full access to this article
View all access options for this article.
References
1.
SiegelRNaishadhamDJemalA. Cancer statistics, 2013.
CA Cancer J Clin2013; 63:
11–30.
WeinstockBWardSCHarpazNWarnerRRItzkowitzSKimMK. Clinical and prognostic features of rectal
neuroendocrine tumors. Neuroendocrinology2013; 98:
180–7.
4.
Wan D, Gu W, Xu G, Shen C, Ding D, Shen S,
Wang S, Gong X, He S, Zhi Q. Effects of common polymorphisms rs2910164 in miR-146a and
rs11614913 in miR-196a2 on susceptibility to colorectal cancer: a systematic review
meta-analysis. Clin Transl Oncol. Epub ahead of print 8 January 2014,
DOI:10.1007/s12094-013-1150-x.
5.
DawsonMAKouzaridesT. Cancer epigenetics: from mechanism to
therapy. Cell2012; 150:
12–27.
6.
HeSXieFLiuYTongQMochizukiKLapinskiPEManiRSReddyPMochizukiIChinnaiyanAMMineishiSKingPDZhangY. The histone methyltransferase Ezh2 is a crucial
epigenetic regulator of allogeneic T-cell responses mediating graft-versus-host
disease. Blood2013; 122:
4119–28.
7.
KleerCGCaoQVaramballySShenROtaITomlinsSAGhoshDSewaltRGOtteAPHayesDFSabelMSLivantDWeissSJRubinMAChinnaiyanAM. EZH2 is a marker of aggressive breast cancer and
promotes neoplastic transformation of breast epithelial cells.
Proc Natl Acad Sci U S A2003; 100:
11606–11.
8.
VaramballySDhanasekaranSMZhouMBarretteTRKumar-SinhaCSandaMGGhoshDPientaKJSewaltRGOtteAPRubinMAChinnaiyanAM. The polycomb group protein EZH2 is involved in
progression of prostate cancer. Nature2002; 419:
624–9.
9.
OugolkovAVBilimVNBilladeauDD. Regulation of pancreatic tumor cell proliferation
and chemoresistance by the histone methyltransferase enhancer of zeste homologue
2. Clin Cancer Res2008, pp. 6790–6.
10.
WagenerNHollandDBulkescherJCrnković-MertensIHoppe-SeylerKZentgrafHPritschMBuseSPfitzenmaierJHaferkampAHohenfellnerMHoppe-SeylerF. The enhancer of zeste homolog 2 gene contributes
to cell proliferation and apoptosis resistance in renal cell carcinoma
cells. Int J Cancer2008; 123:
1545–50.
11.
RamanJDMonganNPTickooSKBoorjianSAScherrDSGudasLJ. Increased expression of the polycomb group gene,
EZH2, in transitional cell carcinoma of the bladder. Clin Cancer
Res2005; 11:
8570–6.
12.
WatanabeHSoejimaKYasudaHKawadaINakachiIYodaSNaokiKIshizakaA. Deregulation of histone lysine methyltransferases
contributes to oncogenic transformation of human bronchoepithelial
cells. Cancer Cell Int2008; 8:
15–15.
13.
TanJYangXZhuangLJiangXChenWLeePLKaruturiRKTanPBLiuETYuQ. Pharmacologic disruption of Polycomb-repressive
complex 2-mediated gene repression selectively induces apoptosis in cancer
cells. Genes Dev2007; 21:
1050–63.
14.
LuCHanHDMangalaLSAli-FehmiRNewtonCSOzbunLArmaiz-PenaGNHuWStoneRLMunkarahARavooriMKShahzadMMLeeJWMoraELangleyRRCarrollARMatsuoKSpannuthWASchmandtRJenningsNBGoodmanBWJaffeRBNickAMKimHSGuvenEOChenYHLiLYHsuMCColemanRLCalinGADenkbasEBLimJYLeeJSKundraVBirrerMJHungMCLopez-BeresteinGSoodAK. Regulation of tumor angiogenesis by
EZH2. Cancer Cell2010; 18:
185–97.
15.
FussbroichBWagenerNMacher-GoeppingerSBennerAFälthMSültmannHHolzerAHoppe-SeylerKHoppe-SeylerF. EZH2 depletion blocks the proliferation of colon
cancer cells. PLoS One2011; 6:
e21651–e21651.
16.
RaoZYCaiMYYangGFHeLRMaiSJHuaWFLiaoYJDengHXChenYCGuanXYZengYXKungHFXieD. EZH2 supports ovarian carcinoma cell invasion
and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian
carcinoma patients. Carcinogenesis2010; 31:
1576–83.
17.
MinJZaslavskyAFedeleGMcLaughlinSKReczekEEDe RaedtTGuneyIStrochlicDEMacconaillLEBeroukhimRBronsonRTRyeomSHahnWCLodaMCichowskiK. An oncogene-tumor suppressor cascade drives
metastatic prostate cancer by coordinately activating Ras and nuclear
factor-kappaB. Nat Med2010; 16:
286–94.
18.
TaniguchiHJacintoFVVillanuevaAFernandezAFYamamotoHCarmonaFJPuertasSMarquezVEShinomuraYImaiKEstellerM. Silencing of Kruppel-like factor 2 by the histone
methyltransferase EZH2 in human cancer. Oncogene2012; 31:
1988–94.
19.
MorinRDJohnsonNASeversonTMMungallAJAnJGoyaRPaulJEBoyleMWoolcockBWKuchenbauerFYapDHumphriesRKGriffithOLShahSZhuHKimbaraMShashkinPCharlotJFTcherpakovMCorbettRTamAVarholRSmailusDMoksaMZhaoYDelaneyAQianHBirolIScheinJMooreRHoltRHorsmanDEConnorsJMJonesSAparicioSHirstMGascoyneRDMarraMA. Somatic mutations altering EZH2 (Tyr641) in
follicular and diffuse large B-cell lymphomas of germinal-center origin.
Nat Genet2010; 42:
181–5.
20.
KodachLLJacobsRJHeijmansJvan NoeselCJLangersAMVerspagetHWHommesDWOfferhausGJvan den BrinkGRHardwickJC. The role of EZH2 and DNA methylation in the
silencing of the tumour suppressor RUNX3 in colorectal cancer.
Carcinogenesis2010; 31:
1567–75.
21.
HeSZhouHZhuXHuSFeiMWanDGuWYangXShiDZhouJZhouJZhuZWangLLiDZhangY. Expression of Lgr5, a marker of intestinal stem
cells, in colorectal cancer and its clinicopathological significance.
Biomed Pharmacother2014; 68:
507–13.
22.
HeSBZhaoHFeiMWuYGWangLZhuXGLiDC. Expression of co-signaling molecules CD40-CD40L
and their growth inhibitory effect on pancreatic cancer in vitro.
Oncol Rep2012; 28:
262–8.
23.
LiuPFWuYYHuYWangLHeSBZhuYBZhuXG. PAUF silencing by RNA interference inhibit the
malignant phenotypes in human colorectal cancer cell. Oncol
Rep2013; 30:
213–20.
24.
HeSYuanYWangLYuMZhuYZhuX. Effects of cyclin-dependent kinase 8 specific
siRNA on the proliferation and apoptosis of colon cancer cells.
J Exp Clin Cancer Res2011; 30:
109–109.
25.
ZhengJLiYYangJLiuQShiMZhangRShiHRenQMaJGuoHTaoYXueYJiangNYaoLLiuW. NDRG2 inhibits hepatocellular carcinoma adhesion,
migration and invasion by regulating CD24 expression. BMC
Cancer2011; 11:
1–9.
26.
SimonJALangeCA. Roles of the EZH2 histone methyltransferase in
cancer epigenetics. Mutat Res2008; 647:
21–9.
27.
ArakawaTMasakiTHiraiTDoiSKuratsuneMArihiroKKohnoNYoriokaN. Activation of signal transducer and activator of
transcription 3 correlates with cell proliferation and renal injury in human
glomerulonephritis. Nephrol Dial Transplant2008; 23:
3418–26.
28.
YamadaAFujiiSDaikoHNishimuraMChibaTOchiaiA. Aberrant expression of EZH2 is associated with a
poor outcome and P53 alteration in squamous cell carcinoma of the
esophagus. Int J Oncol2011, pp. 345–53.
29.
ChangCJYangJYXiaWChenCTXieXChaoCHWoodwardWAHsuJMHortobagyiGNHungMC. EZH2 promotes expansion of breast tumor
initiating cells through activation of RAF1-β-catenin signaling.
Cancer Cell2011; 19:
86–100.
30.
ChaseACrossNC. Aberrations of EZH2 in cancer.
Clin Cancer Res2011; 17:
2613–18.
31.
SimonCChagraouiJKroslJGendronPWilhelmBLemieuxSBoucherGChagnonPDrouinSLambertRRondeauCBilodeauALavalléeSSauvageauMHébertJSauvageauG. A key role for EZH2 and associated genes in mouse
and human adult T-cell acute leukemia. Genes Dev2012; 26:
651–6.
32.
HockH. A complex Polycomb issue: the two faces of EZH2
in cancer. Genes Dev2012; 26:
751–5.
33.
KelekarAThompsonCB. Bcl-2-family proteins: the role of the BH3 domain
in apoptosis. Trends Cell Biol1998; 8:
324–30.
34.
FenauxPMuftiGJHellstrom-LindbergESantiniVFinelliCGiagounidisASchochRGattermannNSanzGListAGoreSDSeymourJFBennettJMByrdJBackstromJZimmermanLMcKenzieDBeachCSilvermanLR; International Vidaza High-Risk MDSSurvival Study Group. Efficacy of azacitidine compared with that of
conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a
randomised, open-label, phase III study. Lancet Oncol2009; 10:
223–32.
35.
GhadjarPCouplandSENaIKNoutsiasMLetschAStrouxABauerSBuhrHJThielEScheibenbogenCKeilholzU. Chemokine receptor CCR6 expression level and
liver metastases in colorectal cancer. J Clin Oncol2006; 24:
1910–6.
36.
ChibaTSuzukiENegishiMSarayaAMiyagiSKonumaTTanakaSTadaMKanaiFImazekiFIwamaAYokosukaO. 3-Deazaneplanocin A is a promising therapeutic
agent for the eradication of tumor-initiating hepatocellular carcinoma
cells. Int J Cancer2012; 130:
2557–67.
37.
TanJYangXZhuangLJiangXChenWLeePLKaruturiRKTanPBLiuETYuQ. Pharmacologic disruption of Polycomb-repressive
complex 2-mediated gene repression selectively induces apoptosis in cancer
cells. Genes Dev2007; 21:
1050–63.
38.
LotzeMTMaranchieJApplemanL. Inhibiting antophagy: a novel approach for the
treatment of renal cell cancinoma. Cancer2013, pp. 341–7.
39.
ZhengHYZhangXYWangXFSunBC. Autophagy enhances the aggressiveness of human
colorectal cancer cells and their ability to adapt to apptotic stimulus.
Cacer Biol Med2012; 9:
105–10.
40.
GuWWanDWQianQYYiBGuYLHeZLWangLHeSB. Ambra1 is an essential regulator of autophagy and
apoptosis in SW620 cells: Pro-survival role of Ambra1. Plos
One2014; 9:
e90151–e90151.
41.
VaramballySCaoQManiRSShankarSWangXAteeqBLaxmanBCaoXJingXRamnarayananKBrennerJCYuJKimJHHanBTanPKumar-SinhaCLonigroRJPalanisamyNMaherCAChinnaiyanAM. Genomic loss of microRNA-101 leads to
overexpression of histone methyltransferase EZH2 in cancer.
Science2008; 322:
1695–9.
42.
WanDWHeSBXieBHXuGHGuWShenCLHuYWang XinshengZhiQMWangL. Aberrant expression of miR-199a-3p and its
clinical significance in colorectal cancers. Med Oncol2013; 30:
378–378.
43.
LuJHeMLWangLChenYLiuXDongQChenYCPengYYaoKTKungHFLiXP. MiR-26a inhibits cell growth and tumorigenesis of
nasopharyngeal carcinoma through repression of EZH2. Cancer
Res2011; 71:
225–33.
